EDX Medical Group

What EDX Medical Group does

EDX Medical Group plc is a Cambridge-headquartered, AIM-listed digital diagnostics company that develops and distributes molecular and point-of-care diagnostic tests for oncology, cardiology and infectious diseases, selling primarily to NHS trusts, private hospital groups, healthcare professionals and screening programmes in the UK, with exclusive distribution extensions into the Nordics for the cResponse assay. Its revenue model combines one-time test/service fees (e.g., TC100 at £875 per test, COVID PCR at £55), point-of-care hardware sales, and exclusive distribution economics from Caris Life Sciences molecular profiling platforms (MI Profile, MI Tumor Seek, Caris Assure) and Curesponse's cResponse functional tumour test; direct enterprise field sales are the primary go-to-market, supplemented by partnerships with hospital groups, charities and academic institutions.

The product portfolio layers proprietary in-house tests — the Prostate Cancer 'Super Test' (100+ biomarker AI algorithm, 96-99% expected sensitivity/specificity, patent pending), TC100 testicular cancer blood test (miR-371a-3p combined with AFP/β-hCG/LDH), BC95 advanced bowel cancer service (combining EarlyTect, qFIT and hereditary risk assessment), and an in-development ARDP pneumonia ICU test and 5FU pharmacogenomic test — on top of distributed Caris and Curesponse platforms, with an in-house molecular biology laboratory in Cambridge underpinning laboratory-based work and point-of-care devices enabling bedside use. The company has expanded through acquisition (Torax Biosciences in February 2023 and Hutano Diagnostics in September 2023) and a network of co-development relationships with Thermo Fisher, Oxford University Innovation, University of Cambridge, UKHSA and Cancer Research UK.

Financially, EDX is an early-stage commercial-stage business: H1 FY2026 revenue of £173,045 represented a ninefold year-over-year increase but off a near-zero base, against a widened £2.29M half-year loss and a cash position reduced to £124,794, supported by a £2M founder convertible loan note (January 2025), a £4M post-period raise (December 2025) and a £3.5M prostate-programme-specific raise (February 2026), with shares admitted to AIM in May 2026. Operational highlights include a four-year Cambridge University Hospitals NHS Foundation Trust service agreement for the ARDP ICU test and primary delivery-partner role in the Scottish Prostate Cancer Initiative targeting 25,000 PSA tests across Scotland in 2026.

Name

EDX Medical Group

Legal name

EDX Medical Group plc

Website

https://edxmedical.co.uk

Company type

Public

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

EDX Medical Group plc is a Cambridge-based, AIM-listed digital diagnostics company that develops and distributes molecular and point-of-care diagnostic tests for oncology, cardiology and infectious diseases, selling to NHS trusts, private hospitals, healthcare professionals and population screening programmes primarily in the UK.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)

akta.pro secondary industries

Companion Diagnostics (CDx) & Therapy Selection Assays (HLAAALAF), Companion Diagnostics (CDx) Development & Commercialization (HLAAANAC), Companion Diagnostics (CDx) Development & Trial Testing Support (HLAGAEAJ)

Keywords

• Molecular diagnostic testing
• Cancer diagnostic services
• Point-of-care diagnostics
• Precision oncology tests
• Infectious disease diagnostics

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

1. Diagnostic Testing Services: Laboratory-based diagnostic tests for cancer, cardiovascular diseases, and infectious diseases. Includes tumour profiling, blood-based testing, and tissue analysis services offered to healthcare professionals and organisations.
2. Point-of-Care Testing: Point-of-care devices for bedside use enabling rapid patient test results at healthcare facilities.
3. Product Distribution: Distribution agreements with partners like Caris Life Sciences for exclusive distribution of diagnostic products in the UK, generating revenue through product distribution.
4. Acquisition Integration: Strategic acquisitions of companies like Torax Biosciences and Hutano Diagnostics expand diagnostic development capabilities and product portfolio.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

EDX Medical develops, distributes, and performs digital diagnostic tests and services for cancer, cardiovascular disease, and infectious diseases. Its molecular biology laboratory in Cambridge delivers laboratory-based tests while partner-supplied point-of-care devices enable bedside results. Revenue is generated through fee-per-test laboratory services, proprietary AI-driven cancer diagnostics (BC95, TC100, prostate 'super test'), and exclusive UK/Nordic distribution of third-party platforms from Caris Life Sciences and Curesponse.

Product overview

EDX Medical Group offers a comprehensive portfolio of digital diagnostic products and services for cancer, cardiovascular, and infectious diseases. The portfolio consists of: (1) Caris molecular profiling platforms (MI Profile, MI Tumor Seek, Caris Assure) providing comprehensive DNA/RNA/protein analysis with AI tools for precision oncology; (2) cResponse functional tumour testing platform for ex vivo drug response assessment; (3) cancer-specific testing services including BC95 bowel cancer testing (combining EarlyTect, qFIT, and hereditary testing), TC100 testicular cancer testing (miR-371a-3p with classical markers), and prostate cancer super test (100+ biomarkers with AI algorithm); (4) hereditary cancer testing via BGI Genomics SENTIS NGS panels covering 100+ genes; (5) infectious disease tests including ARDP pneumonia ICU test and multiplex sepsis test (in development); (6) pharmacogenomic testing for 5FU chemotherapy (in development); and (7) PCR COVID-19 testing service. The company operates its molecular biology laboratory in Cambridge, UK, and distributes partner products including Caris Life Sciences and Curesponse assays exclusively in the UK.

Differentiator

Problem solved

Functional benefit

Brands

• TC100: Combined blood testing service for testicular germ cell tumours combining miR-371a-3p (M371) with classical serum markers (AFP, β-hCG, LDH)
• BC95
• Prostate cancer 'super test'
• qFIT
• EarlyTect
• ARDP

Products and services

• BC95 Advanced Bowel Cancer Testing Service Integrated bowel cancer testing service combining the EarlyTect stool DNA methylation test, hereditary cancer risk assessment via multi-gene germline testing, and qFIT, offering sensitivity exceeding 95% across stages 1-4 bowel cancer for healthcare professionals and screening programmes.
• TC100 Testicular Cancer Blood Test Combined blood testing service for testicular germ cell tumours integrating the miR-371a-3p (M371) microRNA biomarker with classical serum markers (AFP, β-hCG, LDH), supporting diagnosis, treatment assessment, and long-term follow-up; demonstrated 100% success rates in post-diagnosis surveillance. Priced at £875 per test.
• Prostate Cancer Super Test

Quantifiable outcome

• 95%+ sensitivity for bowel cancer detection across stages 1-4
• +5 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability11 records

Feature6 records

Partnerships

Ten partnerships are on record, tiered major, core and supporting.

• Graham Fulford Charitable TrustmajorStrategic or Co-development Partner · 26 March 2026Partnership for Scottish Prostate Cancer Initiative delivering diagnostic tests and laboratory services. Initiative aims to offer free PSA testing to 25,000 men aged 40-80 across Scotland in 2026, with findings to be shared with NHS Scotland.
• Cambridge University Hospitals NHS Foundation TrustcoreStrategic or Co-development Partner · 8 August 2025Partnership with ICU at Cambridge University Hospitals to complete development of pneumonia test for critically ill NHS patients. Test will identify DNA/RNA of microbes causing lung infection with results available in 60 seconds using digital technology. Four-year service agreement for ICU use at Addenbrooke's Hospital.
• Spire Healthcare Group plccoreStrategic or Co-development Partner · 16 June 2025MOU signed to apply EDX Medical's diagnostic innovations including promoting each other's clinical products and services, establishing innovative patient referral and treatment pathways, and developing joint healthcare propositions based on improved understanding of patient biology and personalised treatments.
• Caris Life SciencescoreChannel Partner/ Reseller/ DistributorPartnership and distribution agreement with Caris Life Sciences, US-based next-generation AI TechBio and precision medicine company, to exclusively distribute key Caris products and medical AI solutions in the UK. Includes tumour biopsy molecular profiling (MI Profile), liquid biopsy molecular profiling (MI Tumour Seek), and minimum residual disease testing (MI Assure).
• Thermo Fisher Scientific EMEA LtdcoreStrategic or Co-development PartnerCollaborative agreement to jointly develop and potentially commercialise clinical-grade assays including novel cancer diagnostic solutions. Collaboration will harness Thermo Fisher's technologies to deliver advanced testing solutions, including a proprietary assay for personalised radiotherapy and a novel chemotherapy toxicity assay. Part of multi-project collaboration under EDX's strategic initiatives.
• Curesponse LtdcoreChannel Partner/ Reseller/ DistributorExclusive distribution agreement for cResponse™ cancer assay in UK, Sweden, Finland, Norway and Denmark. cResponse™ is an ex vivo functional platform developed by Curesponse that assesses how individual patient's tumour tissue responds to selected medicines. EDX Medical hosts exclusive webinars and educational events for Curesponse products.
• University of CambridgecoreStrategic or Co-development PartnerCollaboration with University of Cambridge and UK Health Security Agency (UKHSA) on development of ARDP pneumonia test for ICU patients. Cambridge Enterprise licensed IP for the assay developed by Cambridge University Hospitals NHS Foundation Trust.
• Oxford University Innovation Ltd (OUI)coreStrategic or Co-development PartnerExclusive agreement to in-license new intellectual property from Oxford and Birmingham Universities for 5FU/capecitabine pharmacogenomic drug safety test. Research funded by Cancer Research UK. New test will be first and only UK test to fully meet AMP tier I and II guidelines.
• Cancer Research UKsupportingOthersResearch funder for 5FU/capecitabine pharmacogenomic test development at Oxford and Birmingham Universities.
• GenomictreesupportingTechnology or IntegrationAgreement with Genomictree of South Korea to include EarlyTect® C colorectal cancer biomarker test in BC95 service. First UK availability of epigenetic colorectal cancer biomarker test measuring aberrant SDC2 promoter region methylation.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Caris Life Sciences: Caris is the developer of MI Profile, MI Tumor Seek, and Caris Assure, which EDX exclusively distributes in the UK. As the underlying technology originator and a leading US precision oncology company, Caris is the closest functional peer to EDX's core offering.
• Foundation Medicine: Foundation Medicine (a Roche subsidiary) provides comprehensive genomic profiling services (FoundationOne CDx, FoundationOne Liquid CDx) used by oncologists worldwide. It is a direct competitor in the molecular profiling and AI-augmented diagnostics category that EDX targets.
• Guardant Health: Guardant Health is a leading precision oncology company offering blood-based liquid biopsy tests (Guardant360, Guardant Reveal). It competes directly with EDX's Caris Assure blood-based tumour profiling service in the UK oncology diagnostics market.
• Tempus: Tempus is an AI-powered precision medicine company offering molecular profiling and data analytics for oncology. Its combination of NGS testing, AI/ML interpretation, and clinical decision support closely mirrors EDX's diagnostic-plus-AI positioning.
• Personalis: Personalis provides comprehensive tumour profiling (NeXT Personal) using whole-genome and transcriptome sequencing plus AI-driven interpretation. It is a direct competitor in the AI-enabled molecular profiling segment that EDX distributes from Caris.
• NeoGenomics: NeoGenomics provides oncology-focused clinical laboratory services including molecular profiling and AI-driven diagnostics. It is a direct peer as a specialised clinical lab serving oncologists with advanced testing services.
• Veracyte: Veracyte develops genomic tests for cancer diagnosis (Decipher, Afirma, Percepta) using AI-enabled molecular analysis. It is a direct competitor in specialty oncology molecular diagnostics with a similar laboratory-services-plus-AI model.
• Curesponse: Curesponse developed the cResponse ex vivo functional tumour platform, which EDX distributes exclusively in the UK and Nordics. As the underlying technology creator, Curesponse is a direct functional peer and partner for functional precision oncology.

Broad incumbents

• Exact Sciences: Exact Sciences is a major cancer screening and diagnostics company (Cologuard, Oncotype DX). It is a broad incumbent competing across colorectal cancer screening and oncology diagnostics where EDX operates with the BC95 bowel cancer service.

Regional players

• Yourgene Health: Yourgene Health (now part of Novacyt) is a UK-based molecular diagnostics company offering reproductive health and oncology testing. It is a comparable UK-focused molecular diagnostics peer serving NHS and private healthcare markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/edx-medical

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries2 records

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EDX Medical Group